Metabolic syndrome is a multifactorial disorder associated with insulin resistance, obesity, hypertension and dyslipidemia, in which increased risk factors promote cardiovascular diseases and diabetes. Early diagnosis is essential for effective management and efforts toward prevention of complications. The appearance of the nanobiosensors is considered as an innovative approach to develop novel diagnostic tools which utilize features of the nanomaterials to achieve high sensitivity, specificity and rapid detection of multiple metabolic biomarkers at a time. Compared to many other methods, these sensors are simple to introduce, fast and allow real-time monitoring and are also possible to integrate with wearable devices and digital health platforms to provide a personalized and continuous health management. Challenges to nanobiosensor development include biocompatibility, sensor stability and regulatory hurdles which are being addressed thanks to progress in nanotechnology, materials science and data analytics. In the end, nanobiosensors hold tremendous promise to revolutionize metabolic syndrome diagnostics by providing opportunity for early detection, precise monitoring and personalized therapeutic intervention which will improve patient outcomes and decrease disease burden.